Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.04 +0.99%

+$0.09 today

Market cap
$590.04M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 1.13M

Average 1.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$23.93M

FY 2025 · Annual

Investing Cash Flow

-$7.21M

FY 2025 · Annual

Financing Cash Flow

$107.39M

FY 2025 · Annual

+573.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.38M)(8.23M)(15.6M)(21.61M)(29.44M)
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
Deferred Income Tax00000
Stock-Based Compensation218.98K624.07K2.57M3.02M2.44M
Change in Working Capital(391.04K)195.21K1.65M3.97M2.7M
Accounts Receivables97.67K(236.38K)(893.4K)(971.53K)2.06M
Inventory00000
Accounts Payables(106.06K)1.13M2.43M4.4M1.03M
Other Working Capital(382.64K)(700.15K)111.84K537.2K(384.74K)
Other Non-Cash Items22.96M002.94M0
Operating Cash Flow(1.59M)(7.41M)(11.37M)(14.6M)(23.93M)
Capital Expenditures(802)3(52.09K)(1.18M)(732.93K)
Acquisitions (Net)00000
Purchases of Investments0000(6.48M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(802)0(52.09K)(1.18M)(7.21M)
Debt Repayment200K(50K)000
Common Stock Issued18.65M3.39M15.7M15.95M107.39M
Common Stock Repurchased0(99.96K)000
Dividends Paid00000
Other Financing Activities0(6.72K)(232K)00
Financing Cash Flow18.85M3.23M15.46M15.95M107.39M
Effect of Forex Changes(5.43K)(31.52K)33.09K(3.62K)3.84K
Net Change in Cash17.25M(4.21M)4.07M172.16K76.25M
Free Cash Flow(1.59M)(7.41M)(11.42M)(15.77M)(24.66M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$29.4M
+ D&A$364.5K
+ Stock-Based Comp$2.4M
+ Deferred Tax$0
+ Working Capital$2.7M
+ Other Non-Cash$0
= Operating Cash Flow-$23.9M
- Capex-$732.9K
= Free Cash Flow-$24.7M

Analysis

FY2025 free cash flow is -$24.7M. FCF conversion is 83.8% of net income. Operating cash flow was -$23.9M, with capex of -$732.9K. The largest bridge item is Working Capital at $2.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingOct 27, 2026
8-KCurrent reportSep 30, 2026
424B5424B5 filingSep 29, 2026

Does IMMX generate free cash flow?

Immix Biopharma, Inc. (IMMX) generated -$24.66M of free cash flow in fiscal 2025.

How much operating cash flow does IMMX produce?

Operating cash flow was -$23.93M, before capital expenditures of $732,925.00.